DICE Insider Trading

DICE Therapeutics, Inc. (DICE) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $2.27B, listed on NASDAQ, employing roughly 71 people, carrying a beta of 0.00 to the broader market. DICE Therapeutics, Inc. Led by J. Kevin Judice, public since 2021-09-15.

In the last 12 months, DICE Therapeutics, Inc. insiders made 0 buy transactions and 0 sale transactions.

DateNameTypeSharesPriceValue
Aug 9, 2023RA CAPITAL MANAGEMENT, L.P.D-Return21,250$14.98$318.3K
Aug 9, 2023RA CAPITAL MANAGEMENT, L.P.U-Tender786,407$0.00$79
Aug 9, 2023TETLOW SHAROND-Return21,250$14.98$318.3K
Aug 9, 2023TETLOW SHAROND-Return49,841$0.00$5
Aug 9, 2023TETLOW SHAROND-Return13,800$17.00$234.6K
Aug 9, 2023Simson JakeD-Return21,250$14.98$318.3K
Aug 9, 2023Scopa James PaulD-Return13,800$17.00$234.6K
Aug 9, 2023Scopa James PaulD-Return21,250$14.98$318.3K
Aug 9, 2023Scopa James PaulD-Return25,722$0.00$3
Aug 9, 2023Robertson Scott M.D-Return56,920$17.00$967.6K

How to Read DICE Insider Activity

Net insider activity is balanced over the trailing twelve months: 0 buys against 0 sales. Balanced activity typically reflects routine compensation-related vesting and tax-driven liquidity rather than directional information signals. The transaction table above includes the filer's reporting name, transaction type, share count, per-share price, and total dollar value where computable. For options traders, insider activity is one input to event-driven sizing alongside earnings calendar, analyst-rating cluster moves, and the implied-vol surface. Form 4 filings (the dominant Section 16 reporting form) must be submitted within two business days of the transaction; clusters of buys across multiple insiders within a short window are the strongest informational pattern. SEC EDGAR carries the underlying source filings for verification and additional historical depth.

Learn how insider trading is reported and how to read the data →